RG6382 / Roche - LARVOL DELTA

Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus (ACR Convergence 2024) - P1 | "RO7507062 was designed as a next generation off-the-shelf B-cell depleter dedicated for patients with autoimmune diseases. A first-in-human study in patients with SLE is ongoing."

P1 data • B Cell Non-Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus • CD20 • CD34

CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2024) - P1 | "RO7507062 was designed as a next generation off-the-shelf B-cell depleter dedicated for patients with autoimmune diseases. A first-in-human study in patients with SLE is ongoing."

P1 data • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus • CD20 • CD34

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus